Mutations in the AUH gene cause 3-methylglutaconic aciduria type I
โ Scribed by T.B. Nga Ly; Verena Peters; K. Michael Gibson; Michael Liesert; Wolfgang Buckel; Bridget Wilcken; Kevin Carpenter; Regina Ensenauer; Georg F. Hoffmann; Matthias Mack; Johannes Zschocke
- Publisher
- John Wiley and Sons
- Year
- 2003
- Tongue
- English
- Weight
- 166 KB
- Volume
- 21
- Category
- Article
- ISSN
- 1059-7794
No coin nor oath required. For personal study only.
โฆ Synopsis
The conversion of 3-methylglutaconyl-CoA to 3-hydroxy-3-methylglutaryl-CoA is the only step in leucine catametabolism yet to be characterized at enzyme and DNA levels. The deficiency of the putative mitochondrial enzyme 3-methylglutaconyl-CoA hydratase associates with the rare organic aciduria 3-methylglutaconic aciduria type I (MGA1), but neither the enzyme nor its gene have been described in any organism. Here we report that human 3-methylglutaconyl-CoA hydratase is identical with a previously described RNA-binding protein (designated AUH) possessing enoyl-CoA hydratase activity. Molecular analyses in five patients from four independent families revealed homozygosity or compound heterozygosity for mutations in the AUH gene; most mutations are predicted to completely abolish protein function. Mutations identified include c.80delG, R197X, IVS8-1G>A, A240V, and c.613_614insA. Clinical severity of MGA1 in published patients has been quite variable. Included in the present study is an additional patient with MGA1 who was detected by neonatal screening and has remained asymptomatic up to his present age of 2 years. The boy is homozygous for an N-terminal frameshift mutation in the AUH gene. Complete absence of 3-methylglutaconyl-CoA hydratase/AUH appears to be compatible with normal development in some cases. Further work is required to identify external or genetic factors associated with development of clinical problems in patients with MGA1.
๐ SIMILAR VOLUMES
Tyrosinemia type I is an inborn error of metabolism caused by a deficiency in the last enzyme of the tyrosine catabolic pathway, fumarylacetoacetate hydrolase (FAH). The disease has been reported worldwide with varying incidence. Recently, there has been considerable progress in identifying mutation
## Abstract A diagnosis of 3โmethylglutaconic aciduria type I (OMIM: 250950) based on elevated urinary excretion of 3โmethylglutaconic acid (3MGA), 3โmethylglutaric acid (3MG) and 3โhydroxyisovaleric acid (3HIVA) was made in a 61โyearโold female patient presenting with leukoencephalopathy slowly pr
We identified three different point mutations in the glutaryl-CoA dehydrogenase (GCDH) gene in two unrelated Japanese patients with glutaric aciduria type I (GA-I). One patient was a homozygote for Arg355His and the other a compound heterozygote for Ser305Leu and Met339Val. Arg355His and Met339Val a